Publication: Dynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging identifies glioblastoma immunohistochemical biomarkers via tumoral and peritumoral approach: A pilot study
dc.contributor.author | Öztürk, Kerem | |
dc.contributor.author | Soylu, Esra | |
dc.contributor.author | Tolunay, Şahsine | |
dc.contributor.author | Narter, Selin | |
dc.contributor.author | Hakyemez, Bahattin | |
dc.contributor.buuauthor | Özturk, Kerem | |
dc.contributor.buuauthor | Soylu, Esra | |
dc.contributor.buuauthor | TOLUNAY, ŞAHSİNE | |
dc.contributor.buuauthor | NARTER, SELİN | |
dc.contributor.buuauthor | HAKYEMEZ, BAHATTİN | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı. | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı. | |
dc.contributor.orcid | 0000-0001-9664-2347 | |
dc.contributor.orcid | 0000-0002-3425-0740 | |
dc.contributor.researcherid | AAI-2318-2021 | |
dc.contributor.researcherid | E-1228-2018 | |
dc.contributor.researcherid | AAI-1612-2021 | |
dc.contributor.researcherid | DSW-1175-2022 | |
dc.contributor.researcherid | FOL-7699-2022 | |
dc.date.accessioned | 2024-07-12T06:24:52Z | |
dc.date.available | 2024-07-12T06:24:52Z | |
dc.date.issued | 2019-04-09 | |
dc.description.abstract | OBJECTIVE: We aimed to evaluate the usefulness of dynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging (DCE-pMRI) to predict certain immunohistochemical (IHC) biomarkers of glioblastoma (GB) in this pilot study.METHODS: We retrospectively reviewed 36 patients (male/female, 25:11; mean age, 53 years; age range, 29-85 years) who had pretreatment DCE-pMRI with IHC analysis of their excised GBs. Regions of interest of the enhancing tumor (ER) and nonenhancing peritumoral region (NER) were used to calculate DCE-pMRI parameters of volume transfer constant, back flux constant, volume of the extravascular extracellular space, initial area under enhancement curve, and maximum slope. IHC biomarkers including Ki-67 labeling index, epidermal growth factor receptor (EGFR), oligodendrocyte transcription factor 2 (OLIG2), isocitrate dehydrogenase 1 (IDH1), and p53 mutation status were determined. The imaging metrics of GB with IHC markers were compared using the Kruskal-Wallis test and Spearman correlation analysis.RESULTS: Among 30 patients with available IDH1 status, 14 patients (46.6%) had IDH1 mutation. EGFR amplification was present in 24/36 (66.6%) patients. Mean Ki-67 labeling index was 29% (range, 1.5%-80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%). Various DCE-pMRI parameters gathered from the ER and NER were significantly correlated with IDH1 mutation, EGFR amplification, and OLIG2 expression (P < 0.05). Ki-67 labeling index showed a strong positive correlation with initial area under enhancement curve (r = 0.619; P < 0.001).CONCLUSIONS: DCE-pMRI could determine surrogate IHC biomarkers in GB via tumoral and peritumoral approach, potential targets for individualized treatment protocols. | |
dc.identifier.doi | 10.1016/j.wneu.2019.04.089 | |
dc.identifier.endpage | E208 | |
dc.identifier.issn | 1878-8750 | |
dc.identifier.startpage | E195 | |
dc.identifier.uri | https://doi.org/10.1016/j.wneu.2019.04.089 | |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S1878875019310812 | |
dc.identifier.uri | https://hdl.handle.net/11452/43219 | |
dc.identifier.volume | 128 | |
dc.identifier.wos | 000475895100022 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Elsevier Science | |
dc.relation.journal | World Neurosurgery | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Microvascular permeability | |
dc.subject | Genomic biomarkers | |
dc.subject | Histogram analysis | |
dc.subject | Mutation status | |
dc.subject | Mr | |
dc.subject | Glioma | |
dc.subject | Parameters | |
dc.subject | Differentiation | |
dc.subject | Lymphoma | |
dc.subject | Survival | |
dc.subject | Dynamic contrast-enhanced t1-weighted perfusion mr imaging (dce-pmri) | |
dc.subject | Epidermal growth factor receptor (EGFR) | |
dc.subject | Glioblastoma (GB) | |
dc.subject | Isocitrate dehydrogenase 1 (IDH1) | |
dc.subject | Oligodendrocyte transcription factor 2 (OLIG2) | |
dc.subject | Neurosciences & neurology | |
dc.subject | Surgery | |
dc.title | Dynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging identifies glioblastoma immunohistochemical biomarkers via tumoral and peritumoral approach: A pilot study | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 13dc6562-e9fe-42fa-8973-dcd80444844e | |
relation.isAuthorOfPublication | d0f32b74-f424-4145-b555-18eb0cdfb10a | |
relation.isAuthorOfPublication | 9ad8c0f1-5154-4a82-b029-77c58cb35066 | |
relation.isAuthorOfPublication.latestForDiscovery | 13dc6562-e9fe-42fa-8973-dcd80444844e |